An interventional study of Normobaric Oxygen and Placebo in Psychosis, Schizophrenia and First-episode Psychosis, sponsored by Nicholas Breitborde. Terminated at 1 site in United States. Open to participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Nicholas Breitborde · Not applicable, Interventional, and Treatment
Vendor unable to continue to provide oxygen concentrators
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.
Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 659th largest by enrollment of the 682 interventional ones that give a count, is one of 42 that started in 2019, is one of 338 with no phase, and was the 581st registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 12–30
Case Western Reserve University · Sites in United States
Ages 18–50
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 15 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
759 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 110 · Phase 3 68 · Phase 4 121
First in 1984; this study’s year is marked. 42 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 60 across the 682 interventional studies, 123 across the 67 observational. Of the 612 that completed or were terminated, 293 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 759 have an industry lead sponsor. The 10 most frequent:
Nicholas Breitborde is the lead sponsor of 2 studies on the registry; none are open to participants now.
Nicholas Breitborde has 2 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
41 of the studies in Psychotic Disorders with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT04411225Phase 3University of California, San DiegoEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | 2026-12 |
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT05558332University of California, IrvineYouth Nominated Support Team | 2026-11 |
| NCT05457127University of California, San DiegoObstructive Sleep Apnea Treatment in Serious Mental Illness | 2026-11 |
Add all 41 to your calendar (.ics) → With an account.
Among the 759 studies in Psychotic Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Functional deficits in prefrontal, limbic, and temporal regions of the brain are well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may contribute to such pathology, and effective functioning of mitochondrial activity in the brain in dependent on a sufficient supply of oxygen. These data suggest that oxygen therapy may improve symptoms in individuals with psychosis. This small pilot study will test this hypothesis.
Individuals with first-episode psychosis will be randomized to receive either (i) 4 weeks of nightly normobaric oxygen therapy (40% FiO2) or (ii) 4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2). Participants will be blinded to what condition they receive. Both conditions will be delivered via nasal cannula connected to oxygen concentrators at five liters per minute (lpm), and participants will be instructed to complete the intervention overnight while sleeping. At the end of the 4 week period, all individuals will receive an additional 4 weeks of unblinded (i.e., "open label") nightly normobaric oxygen therapy (40% FiO2). Study assessments will be completed at (i) enrollment; (ii) 4 weeks after enrollment, and (iii) 8 weeks after enrollment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 weeks of nightly normobaric oxygen therapy (40% FiO2)
Device: Normobaric Oxygen
4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)
Device: Placebo
40% FiO2 for 4 weeks
21% FiO2 for 4 weeks
Change from baseline in cognitive functioning
Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).
Time frame: 4 weeks
Change from baseline in quality of life
Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF.
Time frame: 4 weeks
Change from baseline in social functioning
Change in scores on the Global Functioning: Social Scale. Scores on this measure range from 1-10 with higher scores indicating greater social functioning
Time frame: 4 weeks
Change from baseline in role functioning
Change in scores on the Global Functioning: Role Scale. Scores on this measure range from 1-10 with higher scores indicative of greater role functioning.
Time frame: 4 weeks
Change from baseline in health-related quality of life
Change in scores on the RAND 36-Item Health Survey.
Time frame: 4 weeks
Change from baseline in suicidality
Change in occurrence in suicidal thoughts or behaviors as assessed using the Columbia Suicide Severity Rating Scale. This is a categorical rating scale that identifies the presence or absence of specific levels of severity of suicidal ideation and behavior.
Time frame: 4 weeks
Change from baseline in substance use severity
Change in scores on the HABITS scale. This scale assesses the absolute values of use of specific substances (e.g., number of cigarettes smoked)
Time frame: 4 weeks
Change from baseline in service utilization
Change in scores on the Modified Service Use and Resources Form for Schizophrenia
Time frame: 4 weeks
Change in Sleep
Change in scores on the Pittsburgh Sleep Quality Index.
Time frame: 4 weeks
Change from baseline in medication adherence
Change in scores on the Medication Adherence rating Scale. Scores on this scale range from 0-10 with higher scores indicative of greater medication adherence.
Time frame: 4 weeks
Plan to share: No
Ran from Dec 2019 to primary completion in Oct 2026, 82 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Vendor unable to continue to provide oxygen concentrators
Vendor unable to continue to provide oxygen concentrators
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nicholas Breitborde